Patents by Inventor Lex M. Cowsert

Lex M. Cowsert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5821050
    Abstract: A method for screening candidate antiviral drugs by monitoring papillomavirus replication in vitro in the presence of candidate drugs is provided.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: October 13, 1998
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Lex M. Cowsert, Paul R. Clark
  • Patent number: 5811232
    Abstract: Oligonucleotides and oligonucleotide analogs are provided which are capable of antisense interaction with messenger RNA of papillomavirus. Such oligonucleotides or oligonucleotide analogs can be used for diagnostics and therapeutics as well as for research purposes. In accordance with preferred embodiments of this invention, oligonucleotide or oligonucleotide analog is provided which is hybridizable with a messenger RNA from a papillomavirus. The oligonucleotide or oligonucleotide analog is able to inhibit the function of the RNA, and accordingly is useful for therapy for infections by such papillomavirus.In accordance with a preferred embodiment, portions of the papillomavirus are targeted for antisense attack. Thus oligonucleotides are preferably provided which hybridize with the E2, E1, E7, or E6-7 messenger RNAs.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: September 22, 1998
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Christopher K. Mirabelli, David J. Ecker, Lex M. Cowsert
  • Patent number: 5756282
    Abstract: Oligonucleotides are provided which are targeted to human papillomavirus E2 transactivator messenger RNA. Such oligonucleotides can be used for diagnostics and therapeutics as well as for research purposes.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: May 26, 1998
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Christopher K. Mirabelli, David J. Ecker, Lex M. Cowsert
  • Patent number: 5681944
    Abstract: Oligonucleotides are provided which are capable of antisense interaction with messenger RNA of papillomavirus. Such oligonucleotides or oligonucleotide analogs can be used for diagnostics and therapeutics as well as for research purposes. In accordance with preferred embodiments of this invention, oligonucleotides are provided which are hybridizable with selected messenger RNA from a human papillomavirus. The oligonucleotide is able to inhibit the function of the RNA, and accordingly is useful for therapy for infections by such papillomavirus. In accordance with a preferred embodiment, portions of the papillomavirus are targeted for antisense attack. Thus oligonucleotides are preferably provided which hybridize with the E2, E6 and E7 messenger RNAs.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: October 28, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Christopher K. Mirabelli, David J. Ecker, Lex M. Cowsert
  • Patent number: 5665580
    Abstract: Antisense oligonucleotides are taught which hybridize to human papilloma virus transcripts. These oligonucleotides when added to tissue culture cells transformed with human papilloma virus inhibit growth of the transformed cell.
    Type: Grant
    Filed: October 14, 1994
    Date of Patent: September 9, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Christopher K. Mirabelli, David J. Ecker, Lex M. Cowsert
  • Patent number: 5580767
    Abstract: Compositions and methods are provided for the treatment and diagnosis of influenza virus infections. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with viral RNAs. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intron/exon junction of influenza virus mRNAs. In additional preferred embodiments, the oligonucleotides are specifically hybridizable with RNA sequences involved in splicing of the viral RNA, or in viral packaging. Methods of treating animals suffering from influenza virus infection are disclosed.
    Type: Grant
    Filed: September 22, 1992
    Date of Patent: December 3, 1996
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Lex M. Cowsert, David J. Ecker
  • Patent number: 5457189
    Abstract: Oligonucleotides are provided which are capable of antisense interaction with messenger RNA of papillomavirus. Such oligonucleotides or oligonucleotide analogs can be used for diagnostics and therapeutics as well as for research purposes. In accordance with preferred embodiments of this invention, oligonucleotide ISIS 2105 is provided which hybridizes with selected messenger RNA from a human papillomavirus. The oligonucleotide is able to inhibit the function of the RNA, and accordingly is useful for therapy for infections by such papillomavirus.In accordance with a preferred embodiment, portions of the papillomavirus are targeted for antisense attack. Thus oligonucleotides are preferably provided which hybridize with the E2, E6 and E7 messenger RNAs.
    Type: Grant
    Filed: March 31, 1992
    Date of Patent: October 10, 1995
    Assignee: Isis Pharmaceuticals
    Inventors: Stanley T. Crooke, Christopher K. Mirabelli, David J. Ecker, Lex M. Cowsert